- 期刊
- OpenAccess
The Effectiveness of Maintenance Pharmacotherapies for Non-Small Cell Lung Cancer
並列摘要
Although current recommendations for the treatment of advanced non-small cell lung cancer (NSCLC) include a maximum of six cycles of platinum-based combination therapy as a first-line approach, most patients experience progression within 3-4 months. Therefore, a new treatment strategy, maintenance therapy, has been proposed, and several large randomized prospective controlled trials have shown benefits with maintenance therapy. Maintenance therapy can be classified as either continuation maintenance, which is defined as a prolongation of a part of the first-line chemotherapy or molecularly targeted agent until progression, or switch-maintenance, which is defined as the administration of a different cytotoxic chemotherapy or molecularly targeted agent immediately after induction therapy. In this article, recent results from large randomized phase III trials regarding maintenance therapy are reviewed in order to evaluate the role of maintenance therapy in NSCLC.
延伸閱讀
- Nair, B. S., Bhanderi, V., & Jafri, S. H. (2011). Current and Emerging Pharmacotherapies for the Treatment of Relapsed Small Cell Lung Cancer. Clinical Medicine Insights: Oncology, (), 223-234. https://doi.org/10.4137/CMO.S5964
- 柯獻欽、鄭高珍（2018）。Chemotherapy and Targeted Therapy in Patients with Advanced Non-small Cell Lung Cancer。內科學誌，29(3)，143-152。https://doi.org/10.6314/JIMT.201806_29(3).04
- 簡采汝、林哲斌（2010）。Maintenance Therapy in Non-Small Cell Lung Cancer。台灣癌症醫學雜誌，26(2)，45-54。https://doi.org/10.6323/JoCRP.2010.26.2.1
- 施穎銘、陳育民（2008）。Targeted Therapy in Non-small Cell Lung Cancer。內科學誌，19(1)，8-13。https://doi.org/10.6314/JIMT.2008.19(1).02
- 羅志剛、季匡華（1995）。Multimodality Treatment of Locally Advanced Non-Small Cell Lung Cancer。放射治療與腫瘤學，2(4)，317-327。https://doi.org/10.6316/TRO/199502(4)317